First, the good news for the Indianapolis-based pharma, from the SERENITY phase 2 study in severely active Crohn’s disease. The trial showed patients treated with the drug mirikizumab saw ...

Eli Lilly has the results it was looking for in a second, confirmatory trial of its anti-IL-23p19 antibody mirikizumab in ulcerative colitis as it waits for the outcome of regulatory reviews in ...

Results showed 92.9% of mirikizumab-treated patients who were in clinical remission at 1 year maintained clinical remission at 2 years. Continuous treatment with mirikizumab was associated with ...

Mirikizumab, a humanized monoclonal antibody targeting the p19 subunit of interleukin (IL)-23, has shown efficacy in ulcerative colitis and was approved by the US Food and Drug Administration (FDA ...